EU approves Avastin for lung cancer

Aug 24, 2007

The European Union has approved the anti-cancer drug Avastin as a first-line treatment for advanced lung cancer.

European officials said the drug, which is already approved in the United States, can be used as a first-line treatment for patients with advanced non-small cell lung cancer in combination with platinum-based chemotherapy.

Swiss drug maker Roche said Avastin is the only first-line therapy to demonstrate improved survival benefits beyond one year in patients with advanced lung cancer, the company said Friday in a release.

Roche said Avastin is the first treatment that inhibits angiogenesis, which is the growth of a network of blood vessels that supply nutrients and oxygen to cancerous tissues.

Avastin targets a naturally occurring protein called VEGF (Vascular Endothelial Growth Factor), a key mediator of angiogenesis, thus choking off the blood supply that is essential for the growth of the tumor and its spread throughout the body

The drug is also used in the treatment of breast, colorectal and kidney cancers.

Copyright 2007 by United Press International

Explore further: Expression of privilege in vaccine refusal

add to favorites email to friend print save as pdf

Related Stories

US panel rejects Avastin for breast cancer use

Jun 29, 2011

An expert panel urged the US Food and Drug Administration on Wednesday to strip the Roche-made drug Avastin of its label for use against breast cancer because it is neither safe nor effective.

FDA panel: Revoke drug's breast cancer approval

Jun 28, 2011

(AP) -- A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the government to remove its ...

Hearing may be end of road for breast cancer drug

Jun 27, 2011

(AP) -- The best-selling cancer drug in the world comes under federal scrutiny once again this week, as drugmaker Roche makes a last-ditch effort to keep Avastin approved for breast cancer, despite evidence ...

Analysis details Avastin's rare fatal side effects

Feb 01, 2011

(AP) -- A new analysis raises fresh questions about the risks of the blockbuster cancer drug Avastin, suggesting the chance of dying from side effects linked to it is higher than the risk for patients on chemotherapy alone.

Recommended for you

Expression of privilege in vaccine refusal

15 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments : 0